ArticleTherapeutic advances in urology

Real-world comparative outcomes of darolutamide- versus abiraterone-based triplet therapy for metastatic hormone-sensitive prostate cancer: a retrospective cohort study.

I-Hsuan Alan Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.